白细胞介素17参与重度免疫相关神经内分泌毒性的证据
本文报告一例间皮瘤患者在接受PD1与TIM3双阻断治疗后出现致死性神经内分泌毒性,表现为胰岛素依赖型糖尿病、垂体炎及肌无力样综合征。体外功能实验显示患者血浆存在树突状细胞刺激活性并诱导CD25+标记,符合Th17刺激特征;细胞因子检测仅见IL17A升高,而健康志愿者及无神经内分泌毒性的免疫治疗患者对照均未升高。作者提出IL17或可作为高级别神经内分泌免疫相关不良事件的诊断与治疗候选靶点,但需更大样本验证。
要点
- PD1与TIM3双阻断后出现致死性神经内分泌毒性,按指南免疫抑制治疗未能避免死亡。
- 患者血浆诱导树突状细胞CD25+标记,符合Th17刺激特征。
- 仅IL17A在患者血浆升高,对照(健康志愿者及无该毒性的免疫治疗患者)未升高。
核心结论
- 若在更大样本中验证,IL17或可作为高级别神经内分泌免疫相关不良事件的诊断与治疗候选靶点。
研究设计与样本
- 对一例接受PD1与TIM3双阻断后发生致死性神经内分泌毒性的间皮瘤患者进行血浆免疫调节活性研究。
- 采用体外功能实验无偏检测血浆树突状细胞调节活性,并以细胞因子磁珠阵列定量细胞因子。
- 对照包括健康志愿者及接受免疫治疗但无神经内分泌毒性的患者。
主要发现
- 按既定指南进行免疫抑制治疗未能阻止致死性结局。
- 患者血浆含树突状细胞刺激活性,诱导CD25+标记,符合T-helper 17刺激特征。
- 患者血浆IL17A升高,未检出其他细胞因子升高;对照组未升高。
临床怎么用
- 对免疫检查点抑制剂治疗中出现高级别神经内分泌毒性者,可考虑检测血浆IL17A作为辅助诊断线索。
- IL17通路或为这类重度免疫相关不良事件的潜在治疗靶点,但须待更大样本验证后用于临床决策。
局限性
- 证据仅来自单例患者,结论需在更大样本中验证。
- 研究为体外功能实验与细胞因子定量,未在体内验证IL17的因果作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Severe neurological and endocrine toxicities are well recognised adverse events of immune checkpoint inhibitors. However, the underlying pathophysiology is poorly understood, and classical circulating markers are often non-informative, making it difficult to obtain a precise diagnosis and to initiate timely and effective treatment. Here we investigated immune-modulating activity in the plasma of a mesothelioma patient who developed fatal neuroendocrine toxicity characterised by insulin-dependent diabetes, hypophisitis and a myasthenia-like syndrome while on treatment with the dual PD1 and TIM3 blockade. METHODS: We used an in vitro functional assay for unbiased detection of plasma dendritic cell-modulating activity, followed by cytokine quantification by the Cytokine Bead Array. RESULTS: Immunosuppressive treatment as per established guidelines could not prevent the fatal outcome. Patient's plasma contained a dendritic cell-stimulating activity that induced specific markers (CD25+) compatible with T-helper 17 stimulation. Consistently, elevated levels of interleukin 17 (IL17A), but no other cytokines, were identified in the patient's plasma but not in controls (healthy volunteers and patients treated with immunotherapy without neuroendocrine toxicities). CONCLUSION: If confirmed in larger series, these data suggest IL17 as a candidate diagnostic and therapeutic target in the management of high-grade neuroendocrine immune-related adverse events.
引用
- Mazzarella L, Giugliano S, D'Amico P, et al. Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity. Eur J Cancer. 2020. PMID: 33186857. doi:10.1016/j.ejca.2020.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。